Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.
Level 5 - mechanism / opinion, no new human data
Preclinical bench, ex vivo cell culture, and animal experimental study with no clinical trial data.
PubMed 11742974 · doi:10.1093/emboj/20.24.6969
What was done
The authors evaluated the antiepileptic drug valproic acid as a histone deacetylase (HDAC) inhibitor across multiple preclinical models. They tested its effects on HDAC enzyme activity in vitro, histone acetylation and transcriptional repression in cultured cells and in vivo, cellular differentiation in carcinoma lines, transformed hematopoietic progenitor cells, and primary leukemic blasts from acute myeloid leukemia patients, as well as tumor growth and metastasis in animal models.
What was found
The abstract reports no numerical values, effect sizes, or statistical metrics. Qualitatively, valproic acid inhibited HDAC activity in vitro, relieved HDAC-dependent transcriptional repression, induced histone hyperacetylation in cultured cells and in vivo, promoted differentiation in transformed and patient-derived cell models, and significantly reduced tumor growth and metastasis formation in animal experiments.
Why it matters
This study identifies an established, widely used antiepileptic agent as an HDAC inhibitor, presenting a biological rationale for drug repurposing in differentiation-based cancer therapy.
Limits
The study is entirely preclinical, relying on in vitro assays, cell cultures, and animal models. The abstract omits sample sizes, animal numbers, dosing concentrations, and exact quantitative outcomes. Findings cannot establish therapeutic efficacy or safe therapeutic windows for oncology indications in humans.
Cited by
- supports Valproate acts as a histone deacetylase inhibitor that globally affects histones across the genome.